Microbion Corp received US$25 million in venture funding

Vancouver and Bozeman MT-based -based Microbion Corp has received US$25-million in venture capital to further develop its lead compound for the treatment of antibiotic-resistant infections. The funding is being provided by the Global Health Sciences Venture Fund, a US$500-million joint venture between Vancouver’s Quark Venture Inc and GF Securities, a Hong Kong-based investment bank. The fund was established in late 2016 to address in biotechnology and health sciences companies addressing unmet medical conditions the innovations in drug development, medical devices, health IT and emerging convergent technologies. Quark Venture is headed by Karimah Es Sabar, who served as president and CEO at the Centre for Drug Research and Development (CDRD) from 2009 to 2016 (R$, May 18/16).